Backed by Big Phar­ma VCs, Palleon ramps up a new ap­proach to im­muno-on­col­o­gy with a $48M start­up round

A cou­ple of years ago, GSK’s ven­ture arm SR One brought in Jim Brod­er­ick as its first-ever en­tre­pre­neur-in-res­i­dence. And to­day, they’re back­ing his new can­cer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER